Investors are facing the sober reality of a twin pandemic, COVID-19, and monkeypox. It’s now clear that the government missed the opportunity...
GSK (NYSE: GSK) has a new mission and that mission is to go after major medical conditions that have no treatment. The...
There’s no question about it. It’s ugly out there. Large caps, crypto, bonds, tech. You name it and they’re all down. We’ve...
Northwest Biotherapeutics (OTCMKTS: NWBO) is now a risk-off biotech trading at a significant discount; in a “sell the news” market, there are...
At first glance Veru, Inc.’s (NASDAQ: VERU) COVID-19 therapy phase 3 top line results were notable but their battle for an emergency...
CytoDyn (OTCMKTS: CYDY) investors waking up to the news of the departure of long term CEO and director Nader Pourhassan are probably...
It’s abundantly clear that there is a large short interest in CytoDyn Inc. (OTCMKTS: CYDY). The bear biotech analyst Adam Feuerstein recently...
Todos Medical (OTCMKTS: TOMDF) was a value play before it started running recently based on sound fundamental analysis, and now investors are...
CytoDyn Inc (OTCMKT: CYDY) has been under considerable selling pressure since April and nothing seems to be able to stop it. In...
The big news circulating this week was of Atea Pharmaceuticals’ (NASDAQ: AVIR) COVID-19 antiviral clinical trial failure, which instantly plummeted the stock...